| scholarly article | Q13442814 |
| P50 | author | Jeremy L. Warner | Q62621350 |
| P2093 | author name string | Jon E Arnason | |
| P2860 | cites work | Alemtuzumab for patients with chronic lymphocytic leukaemia | Q24203628 |
| Characterization of the CAMPATH-1 (CDw52) antigen: biochemical analysis and cDNA cloning reveal an unusually small peptide backbone | Q24318606 | ||
| Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 | ||
| Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions | Q27824806 | ||
| Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
| Peripheral blood but not tissue dendritic cells express CD52 and are depleted by treatment with alemtuzumab | Q28217802 | ||
| Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths | Q28241157 | ||
| Removal of T cells from bone marrow for transplantation: a monoclonal antilymphocyte antibody that fixes human complement | Q28266531 | ||
| Reshaping human antibodies for therapy | Q28290936 | ||
| Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study | Q33342242 | ||
| Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine | Q33344258 | ||
| Phase II study of alemtuzumab in chronic lymphoproliferative disorders | Q33349421 | ||
| Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. | Q33377100 | ||
| Alemtuzumab in clinical practice: a British Columbia experience | Q33378464 | ||
| Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group | Q33385371 | ||
| Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients | Q33394308 | ||
| Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study | Q33394981 | ||
| Fludarabine plus alemtuzumab versus fludarabine alone in patients with previously treated chronic lymphocytic leukaemia: a randomised phase 3 trial | Q33397605 | ||
| Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia | Q33499555 | ||
| Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia | Q34008593 | ||
| Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. | Q34026194 | ||
| The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo | Q34029869 | ||
| Novel therapies for chronic lymphocytic leukemia in the 21st century | Q34069187 | ||
| The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia | Q34249777 | ||
| National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment | Q34382878 | ||
| Alemtuzumab by continuous intravenous infusion followed by subcutaneous injection plus rituximab in the treatment of patients with chronic lymphocytic leukemia recurrence | Q35766117 | ||
| Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia | Q35848136 | ||
| How I treat refractory CLL. | Q36276536 | ||
| Updated guidelines on the management of cytomegalovirus reactivation in patients with chronic lymphocytic leukemia treated with alemtuzumab | Q36616749 | ||
| A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma | Q36892621 | ||
| Etiology and management of tumor lysis syndrome in patients with chronic lymphocytic leukemia. | Q37517161 | ||
| New modalities of therapy in chronic lymphocytic leukemia | Q37543349 | ||
| Management guidelines for the use of alemtuzumab in chronic lymphocytic leukemia | Q37559275 | ||
| ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia | Q37980658 | ||
| Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial | Q38001693 | ||
| PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic | Q38010180 | ||
| CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability | Q39642145 | ||
| The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia | Q39722770 | ||
| Effect of alemtuzumab on neoplastic B cells. | Q40482330 | ||
| Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. | Q40509673 | ||
| Guidelines for clinical protocols for chronic lymphocytic leukemia: recommendations of the National Cancer Institute-sponsored working group | Q41262857 | ||
| Remission Induction in Patients with Lymphoid Malignancies Using Unconjugated CAMPATH-1 Monoclonal Antibodies. | Q41748357 | ||
| Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis | Q41863626 | ||
| Clinical outcome of pretreated B-cell chronic lymphocytic leukemia following alemtuzumab therapy: a retrospective study on various cytogenetic risk categories | Q43064192 | ||
| Low-dose intravenous alemtuzumab therapy in pretreated patients affected by chronic lymphocytic leukemia. A single center experience. | Q43841118 | ||
| Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia | Q43904550 | ||
| Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). | Q44071979 | ||
| Incidence of cytomegalovirus infection and disease in patients with lymphoproliferative disorders treated with alemtuzumab. | Q44100215 | ||
| Cellular immune reconstitution after subcutaneous alemtuzumab (anti-CD52 monoclonal antibody, CAMPATH-1H) treatment as first-line therapy for B-cell chronic lymphocytic leukaemia | Q44324002 | ||
| Excess mortality after treatment with fludarabine and cyclophosphamide in combination with alemtuzumab in previously untreated patients with chronic lymphocytic leukemia in a randomized phase 3 trial. | Q44579242 | ||
| A pilot study of low-dose subcutaneous alemtuzumab therapy for patients with hemotherapy-refractory chronic lymphocytic leukemia. | Q44650460 | ||
| Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia | Q44732855 | ||
| A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL). | Q45129280 | ||
| Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival | Q45287934 | ||
| Reconstitution of the T-cell repertoire following treatment with alemtuzumab (anti-CD52 monoclonal antibody) in patients with B-cell chronic lymphocytic leukaemia | Q45862709 | ||
| Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study. | Q45916399 | ||
| Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. | Q46504755 | ||
| Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial | Q46689599 | ||
| Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network | Q46812536 | ||
| Pilot experience with continuous infusion alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia | Q46817686 | ||
| Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism | Q46845177 | ||
| Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy | Q46881201 | ||
| Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia | Q46913558 | ||
| Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL). | Q47435734 | ||
| Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed? | Q47722904 | ||
| Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration | Q47749207 | ||
| Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia. | Q52007715 | ||
| Alemtuzumab maintenance may safely prolong chemotherapy-free intervals in chronic lymphocytic leukemia. | Q53476801 | ||
| Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy. | Q53962600 | ||
| Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders | Q57053368 | ||
| Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia | Q58041667 | ||
| Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen | Q61651721 | ||
| REMISSION INDUCTION IN NON-HODGKIN LYMPHOMA WITH RESHAPED HUMAN MONOCLONAL ANTIBODY CAMPATH-1H | Q61651778 | ||
| Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia | Q64375929 | ||
| Effects of monoclonal anti-lymphocyte antibodies in vivo in monkeys and humans | Q70507731 | ||
| Differential response in a patient treated with Campath-1H monoclonal antibody for refractory non-Hodgkin lymphoma | Q72209967 | ||
| Subcutaneous CAMPATH-1H in fludarabine-resistant/relapsed chronic lymphocytic and B-prolymphocytic leukaemia | Q73119939 | ||
| CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma | Q77435839 | ||
| Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies | Q78773743 | ||
| High-risk fludarabine-pretreated B-cell chronic lymphocytic leukemia's high response rate following sequential DHAP and alemtuzumab administration though in absence of molecular remission | Q79182827 | ||
| Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria | Q79281118 | ||
| The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53 | Q81340630 | ||
| An Italian retrospective study on the routine clinical use of low-dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients | Q82851509 | ||
| Alemtuzumab in combination with high-dose methylprednisolone is a logical, feasible and highly active therapeutic regimen in chronic lymphocytic leukaemia patients with p53 defects | Q83888306 | ||
| FCA: forget chemoimmunotherapy with alemtuzumab? | Q84268390 | ||
| Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: final analysis | Q84477381 | ||
| An open-label, pilot study of fludarabine, cyclophosphamide, and alemtuzumab in relapsed/refractory patients with B-cell chronic lymphocytic leukemia | Q84576358 | ||
| Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia | Q84947275 | ||
| P433 | issue | 6 | |
| P921 | main subject | lymphocyte | Q715347 |
| chronic lymphocytic leukemia | Q1088156 | ||
| P304 | page(s) | 375-389 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Therapeutic advances in hematology | Q26842172 |
| P1476 | title | Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use | |
| P478 | volume | 3 |
| Q38167350 | Current evaluation of alemtuzumab in multiple sclerosis |
| Q47221234 | New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness |
| Q38510486 | Novel drug therapies in myeloid leukemia |
| Q90457449 | Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities |
| Q38840423 | Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults |
| Q43437611 | Unexplained severe Coombs-negative hemolytic anemia during treatment of refractory chronic lymphocytic leukemia with alemtuzumab. |
| Q64904346 | Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL. |
Search more.